Safety and efficacy of CEUS-guided percutaneous radiofrequency ablation combined with extracting blood from hemangiomas in treatment of hepatic cavernous hemangiomas
10.13929/j.1672-8475.201708016
- VernacularTitle:CEUS引导射频消融联合瘤体内血液抽吸治疗肝血管瘤的安全性及临床效果
- Author:
Xiuyun REN
1
;
Yang YUE
;
Nong GAO
;
Hong NIU
;
Fengdong WU
Author Information
1. 中国武警总医院超声科
- Keywords:
Hemangioma;
Liver neoplasms;
Catheter ablation;
Ultrasonography
- From:
Chinese Journal of Interventional Imaging and Therapy
2018;15(1):33-36
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the safety and efficacy of radiofrequency ablation (RFA) combined with extracting blood from hemangiomas guided with CEUS for treating hepatic cavernous hemangiomas (HCH).Methods Data of 55 patients with 77 lesions of HCH underwent CEUS guided RFA combined with extracting blood from hemangiomas during January 2010 to December 2016 were retrospectively analyzed.Conventional ultrasound and CEUS were performed before therapy,in order to obtain the size and blood supply information of lesions,also performed immediately after treatment and 3 months later to calculate the volume of hemangiomas and the rate of hemangiomas after the treatment,as well as the rate of non-blood supply 3 months after the treatment.Then statistical analysis was done.Results The mean operation time was (31.53±15.89)min,and the blood extracting from hemangiomas was (135.36± 68.13)ml.There was positive correlation between the volume of hemangiomas before treatment and the blood extracting from hemangiomas (r=0.722,P＜0.05).No serious complication occurred among 55 cases,while mild complications happened in 9 cases (9/55,16.36 ％).The volume of hemangiomas decreased immediately and 3 months after treatment (both P＜0.05),and the rate of hemangiomas reducing was (48.76±32.58) ％ and (22.37±35.73) ％,respectively.The rate of non-blood supply 3 months after treatment was 96.10％ (74/77).Conclusion CEUS-guided RFA combined with extracting blood from hemangiomas is an effective and safe method,which has potential to become a first-line therapy.
